Ads
related to: multiple myeloma and peripheral neuropathy- How SARCLISA Works
Watch a Short Video
to See How SARCLISA Works
- Phase 3 Trials
See Study Results
From the Latest Trial
- Treatment Schedule
Learn How SARCLISA Is Given
See the Treatment Schedule
- Safety Information
Read Safety Information
for Patients and Caregivers
- How SARCLISA Works
Search results
Results From The WOW.Com Content Network
The side effects of receiving bortezomib include chronic, distal, and symmetrical sensory peripheral neuropathy and neuropathic pain syndrome which may last for weeks, months, or years after treatment completion. [citation needed] 6) Immunomodulatory drugs, mainly thalidomide, are used to treat multiple myeloma. [3]
MGUS is a relatively stable condition afflicting 3% of people aged 50 and 5% of people aged 70; it progresses to multiple myeloma at a rate of 0.5–1% cases per year; smoldering multiple myeloma does so at a rate of 10% per year for the first 5 years, but then falls off sharply to 3% per year for the next 5 years and thereafter to 1% per year.
Multiple myeloma, mantle cell lymphoma and follicular lymphoma (orphan). Peripheral neuropathy, neutropenia, thrombocytopenia, anaemia, orthostatic hypotension, hepatitis (uncommon/rare), haemorrhage (uncommon/rare), heart failure (uncommon/rare), seizures (uncommon/rare), progressive multifocal leucoencephalopathy (PML) and hearing loss.
Crow–Fukase syndrome, Osteosclerotic myeloma, PEP syndrome, Polyneuropathy-endocrinopathy-plasma cell dyscrasia syndrome, Takatsuki syndrome. [1] Multiple myeloma is usually diagnosed because malignant plasma cells continue to produce an antibody that can be detected as a paraprotein. Specialty: Oncology Symptoms
Chemotherapy-induced peripheral neuropathy Between 30 and 40 percent of patients undergoing chemotherapy experience chemotherapy-induced peripheral neuropathy (CIPN): tingling numbness, intense pain, and hypersensitivity to cold, beginning in the hands and feet and sometimes progressing to the arms and legs. [ 15 ]
Monoclonal gammopathy of undetermined significance (MGUS) is a plasma cell dyscrasia in which plasma cells or other types of antibody-producing cells secrete a myeloma protein, i.e. an abnormal antibody, into the blood; this abnormal protein is usually found during standard laboratory blood or urine tests.